| abstract |
The present invention relates to novel heteroaryl compounds of formula (I), processes for their preparation, pharmaceutical compositions containing them and their use in^the treatment of diseases or disorders mediated by Diacylglycerol acyltransferase 1 enzyme. (DGAT-1), particularly obesity or an obesity related disorder. (I), wherein, Z is selected from unsubstituted or substituted alkylcycloalkyl, unsubstituted or substituted cycloalkyl, unsubstituted or substituted aryl, unsubstituted or substituted heteroaryl and unsubstituted or substituted heterocycle; Y is selected from -Ν(R 4 )-, -N(R 4 )CON(R 5 )-, -N(R 4 )CSN(R 5 )-, -NR 4 C(0)-, -N(R 4 )(C=NR 4 )N(R 5 )-, -C0N(R 4 )-, -NR 4 SO 2 - and -SO 2 NR 4 -; U is selected from (a) and (b), wherein T is -O- or -S-; V is selected from -CONR 4 -, -CSNR 4 -, -C(0). -C(S), -COC(R 4 )(R 5 ) and -S0 2 NR 4 ; R 3 is selected from -COOR p , -CONR p R q , -CONRpSChR, and a carboxylic acid isostere selected from tetrazol-5-yl, 5-trifluorome-hyl-l,2,4-triazol-3-yl, S-(methylsulfonyl)- 1,2,4-triazol-3-yl and 2,5-dihydro-5-oxo-l,2,4-oxadiazol-3-yl; R 1 , R 2 , R 4 , R p and R q are i.a. H and optionally substituted alkyl. |